Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort - PubMed
7 hours ago
- #acute myeloid leukemia
- #KRAS mutation
- #ASXL1 mutation
- Co-mutation of ASXL1 and KRAS defines a novel ultra-adverse-risk subtype of acute myeloid leukemia (AML).
- Patients with ASXL1mut/KRASmut exhibited significantly inferior 2-year overall survival (OS) and relapse-free survival (RFS) rates compared to other mutation subgroups.
- The ASXL1mut/KRASmut co-mutation confers a poor prognosis comparable to TP53 mutations or complex karyotypes.
- Hematopoietic stem cell transplantation (HSCT) showed no significant survival benefit for patients with this co-mutation.
- The study highlights the independent prognostic value of ASXL1mut/KRASmut co-mutation in AML.